Just last week, Angelina Jolie made headlines again when she revealed she had surgery to prevent what she called "another family cancer."
She had already had a double mastectomy because tests showed she was at risk for breast cancer.
[WEB EXTRA: FAQ of PARP Inhibitors | Clinical Trials on PARP Inhibitors ]
Now a cancer trial could give hope to those with breast cancers related to a genetic defect.
“There were no symptoms absolutely no symptoms,” said Doree Garolsky, who calls the diagnosis of breast cancer a shock. “I had 16 years worth of mammograms was very faithful with that so it's not like i wasn't taking care of myself."
Doctors told her cancer had already spread to her bones, there was no cure and her only option was a clinical trial using a unique approach.
It’s called a PARP Inhibitor and is a new class of chemotherapy drugs that have anti-tumor activity.
“Three of our patients have received this drug three out of three have responded favorable to the drug,” said Dr. Charles Vogel of Sylvester Cancer Center.
This class of drugs works specifically on breast cancers related to a genetic defect: BRCA1 AND BRCA 2.
“Basically what the PARP does normally is when DNA is damaged is the PARP inhibitor comes in and repairs the damage,” said Vogel.
But in this case, the object is to damage the DNA in order to kill the cancer cells inhibiting the PARP.
“It would be a breakthrough to make this drug commercially available if these preliminary results we're seeing are truly borne out,” said Vogel.
The treatment involves taking a pill once a day something Garolsky says it's much easier than intravenous chemotherapy, “I feel awesome! I really do.” Reported by Click Orlando 20 hours ago.
She had already had a double mastectomy because tests showed she was at risk for breast cancer.
[WEB EXTRA: FAQ of PARP Inhibitors | Clinical Trials on PARP Inhibitors ]
Now a cancer trial could give hope to those with breast cancers related to a genetic defect.
“There were no symptoms absolutely no symptoms,” said Doree Garolsky, who calls the diagnosis of breast cancer a shock. “I had 16 years worth of mammograms was very faithful with that so it's not like i wasn't taking care of myself."
Doctors told her cancer had already spread to her bones, there was no cure and her only option was a clinical trial using a unique approach.
It’s called a PARP Inhibitor and is a new class of chemotherapy drugs that have anti-tumor activity.
“Three of our patients have received this drug three out of three have responded favorable to the drug,” said Dr. Charles Vogel of Sylvester Cancer Center.
This class of drugs works specifically on breast cancers related to a genetic defect: BRCA1 AND BRCA 2.
“Basically what the PARP does normally is when DNA is damaged is the PARP inhibitor comes in and repairs the damage,” said Vogel.
But in this case, the object is to damage the DNA in order to kill the cancer cells inhibiting the PARP.
“It would be a breakthrough to make this drug commercially available if these preliminary results we're seeing are truly borne out,” said Vogel.
The treatment involves taking a pill once a day something Garolsky says it's much easier than intravenous chemotherapy, “I feel awesome! I really do.” Reported by Click Orlando 20 hours ago.